• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    辉

    辉瑞

    Pfizer Inc.
    企业EST. 1849
    2.6万论文总数
    99.4万引用总数

    辉瑞公司创建于1849年,迄今已有170年的历史,总部位于美国纽约,是全球最大的以研发为基础的生物制药公司。 辉瑞公司的产品覆盖了包括化学药物、生物制剂、疫苗、健康药物等诸多广泛而极具潜力的治疗及健康领域,同时其卓越的研发和生产能力处于全球领先地位。 2020年5月6日消息,美国制药巨头辉瑞周二表示,已开始在美国测试一种实验性疫苗以对抗新冠病毒。辉瑞表示,美国第一批受试者已经接种了新冠实验性疫苗BNT162 。 2020年5月13日,辉瑞制药名列2020福布斯全球企业2000强榜第49位。

    论文量&引用量时间轴

    机构学者

    论文(10000)

    年份
    起
    –
    止
    排序
    1Monitoring of Adverse Events Following 2024–2025 BNT162b2 KP.2 COVID-19 Vaccination in the United States
    Jenny W. Sun, Laura E. Dodge, Shijie Cai,Li Zhou,Florence T. Wang

    Large real-world data studies are needed to understand the safety profile of the 2024–2025 adapted COVID-19 vaccines. This study monitors the occurrence of 20 adverse events of special interest (AESIs) following 2024–2025 BNT162b2 KP.2 COVID-19 vaccination. Individuals age ≥ 6 months vaccinated between 08/22/2024 and 03/10/2025 were identified within the Optum pre-adjudicated database. A self-controlled risk interval design was used to compare the incidence of 20 AESIs during a risk period following vaccination to a subsequent control period among 894,852,024–2025 BNT162b2 COVID-19-vaccinated individuals (median age: 46.9 years). While point estimates were higher in the risk period compared to the control period for non-febrile convulsions/seizures (relative incidence: 1.29; 95% CI: 0.92–1.81) and herpes zoster (relative incidence: 1.05; 95% CI: 0.59–1.85), the magnitude was not significant. No safety signals were identified following 2024–2025 BNT162b2 COVID-19 vaccination among commercially insured individuals in the United States, though the study was underpowered for rare outcomes.

    2027Vaccine(2027)
    引用
    AI阅读
    加入学术空间
    2Valuing Child and Adolescent Health States to Derive Utilities for Use in Economic Evaluation: A Good Practices Report of an ISPOR Task Force.
    Louis S Matza,Donna Rowen, Fleur Chandler,Kim Dalziel, Salah Ghabri,Ernest H Law, Lisa A Prosser, Oliver Rivero-Arias,Koonal Shah,Elly Stolk,Jonathan Wolff,Nancy Devlin

    Economic evaluations of interventions that target or include children require health state utilities (HSUs). Despite the availability of preference-weighted measures for children, methods for valuing child health states and estimating child utilities are not as well established as those for adult HSUs. The objective of this task force was to develop emerging good practice recommendations for valuing child and adolescent health to generate HSUs for use in economic evaluation. This task force identified and described the interrelated methodological choices regarding the valuation of child health to generate HSUs. The task force considered available evidence related to 4 key issues: (1) whose preferences should be sought, (2) whose health is imagined, (3) which method should be used, and (4) the comparability between adult and child utilities. Best practices may vary depending on the modeling context, characteristics of the health states, and the health technology assessment setting in which the HSUs will be used. For any individual study, methods will be informed by empirical evidence, value judgments, and recommendations from healthcare decision makers. Rather than recommending an approach that would apply to every study, this task force presents options to consider when determining the preference elicitation approach to generate utilities for child health states, along with the strengths and limitations of each. Given that child HSUs can affect the outcomes of a cost-utility analysis and subsequent decisions about healthcare resource allocation, this task force recommends that researchers be transparent about methodological choices and their impact on HSUs.

    2026Value in health the journal of the International Society for Pharmacoeconomics and Outcomes Researc...(2026)引用:87
    引用
    AI阅读
    加入学术空间
    3Evaluating the Utility and Constraints of the Competitive Counter Flow (CCF) Assay in OATP1B1 Substrate Profiling
    Sumathy Mathialagan, Mark A. West, Emi Yamaguchi, Hannah M. Moulton,Brendon Kapinos, Sasan Paryad Zanjani,David A. Tess,Emi Kimoto, Manthena V. S. Varma, Sook Wah Yee

    The organic anion transporting polypeptide 1B1 (OATP1B1) plays a critical role in hepatic uptake of a wide range of high- and low-permeability, anionic molecules, particularly those in Extended Clearance Classification System (ECCS) Classes 1 and 3. However, conventional uptake assays using HEK293 cells overexpressing OATP1B1 can yield false-negative results, especially for highly permeable, lipophilic anionic or zwitterionic compounds, where passive diffusion and nonspecific binding may mask transporter-mediated uptake. In this study, we applied the competitive counterflow (CCF) assay to evaluate 58 compounds across different ECCS classes. The assay measures steady-state changes in intracellular [3H]-estradiol-17β-glucuronide retention following exposure to test compounds across multiple concentrations. Several known OATP1B1 substrates, exhibited more than 50

    2026The AAPS Journal(2026)引用:66
    引用
    AI阅读
    加入学术空间
    4Efficacy, Safety, and Immunogenicity of the MATISSE (maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.
    Eric A F Simões,Barbara A Pahud, Shabir A Madhi,Beate Kampmann, Emma Shittu,David Radley,Conrado Llapur, Jeffrey Baker,Gonzalo Pérez Marc,Shaun L Barnabas, Merlin Fausett, Tyler Adam,

    OBJECTIVE:To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF). METHODS:MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants aged 49 years or younger at 24-36 weeks of gestation were randomized (1:1) to receive a single RSVpreF 120 micrograms or placebo dose. Primary efficacy endpoints included newborn and infant severe RSV-associated medically attended lower respiratory tract illness within 180 days after birth. The RSV-A and RSV-B serum neutralizing antibody titers were determined in a subset of pregnant participants and their newborns. RESULTS:In this final analysis, 7,420 pregnant participants were randomized, and 7,307 children were born (RSVpreF n=3,660, placebo n=3,647). Vaccine efficacy , defined as protection against newborn and infant severe RSV-associated medically attended lower respiratory tract illness, was 82.4% (95% CI, 57.5-93.9) and 70.0% (95% CI, 50.6-82.5) within 90 and 180 days of birth, respectively. The RSVpreF induced robust immune responses in pregnant participants and resulted in highly efficient transfer of maternal antibodies to their newborns across subgroups (by gestational age at delivery and at vaccination, number of days from vaccination to delivery, country, maternal age). Final RSVpreF safety results in pregnant and newborn and infant participants were consistent with the primary analysis with no new safety concerns identified. CONCLUSION:This final analysis of MATISSE trial data confirms the primary analysis conclusions: Maternal vaccination with RSVpreF has a favorable safety profile in both pregnant and newborn and infant participants and demonstrates efficacy against RSV-associated lower respiratory tract illness in infants through age 6 months. The RSVpreF induces robust immune responses in pregnant individuals, with corresponding high RSV-neutralizing titers in their newborns. CLINICAL TRIAL REGISTRATION:ClinicalTrials.gov , NCT04424316.

    2026Obstetrics and gynecology(2026)引用:58
    引用
    AI阅读
    加入学术空间
    5Severity of COVID-19 Omicron Variants: A Global Systematic Review
    Deepa Malhotra,Rajeev M. Nepal, Irini Zografaki,Moe H. Kyaw, Pinelopi Nikolopoulou, Rodrigo Sini de Almeida, Santiago M. C. Lopez, Stephen Wiblin, Fraser Williams, Sophie Pope, Isabelle Whittle, Fiona Pearson,

    The continual emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants drives the need to update evidence on coronavirus disease 2019 (COVID-19) severity and disease burden, and better understand the impact on prevention, treatment, and healthcare systems. This systematic review aimed to determine relative disease severity, through comparative measures of hospitalization, intensive care unit admission and mortality, between SARS-CoV-2 variants of concern emerging since Omicron was first identified. A protocol was registered a priori (PROSPERO ID: CRD42024619193). Systematic searches of MEDLINE and EMBASE databases were conducted in November 2024 and supplemented by conference searches from 2022–2024. Population, Exposure, Comparisons, Outcomes (PECO) criteria were used to screen publications for inclusion. Critical appraisal tools published in the Joanna Briggs Institute (JBI) Handbook for Evidence Synthesis were used to assess the risk of bias of the primary studies included. The outcomes associated with Omicron variants, identified by sequencing or predominance periods, included hospitalization, admission to intensive care, death, and various composite endpoints. Thirty-two studies fulfilled the eligibility criteria, most reported on relative disease severity for early Omicron BA.5 (n = 23) and XBB (n = 24) variants. Overall, COVID-19 severity appeared largely comparable across the various Omicron subvariants. Among the subset of studies that directly compared various severity outcomes to earlier SARS-CoV-2 variants (n = 7), some reported modest increases or decreases in severity. However, these differences were generally not statistically significant. Five studies stratifying outcomes by the presence of comorbid conditions noted that comorbidities were predictors of significantly worse COVID-19 disease outcomes (p = 0.000–0.027). Overall, this systematic review found the severity of COVID-19 disease to be comparable among Omicron subvariants. As SARS-CoV-2 subvariants continue to emerge, these results highlight the continuing need for vaccination against SARS-CoV-2 infection alongside early antiviral intervention to support short-term management and long-term reduction of COVID-19-associated morbidity and mortality.

    2026Infectious Diseases and Therapy(2026)引用:52
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 10000 篇论文

    合作机构(100)

    百时美施贵宝公司合作论文 548
    默克制药公司合作论文 444
    礼来公司合作论文 393
    华盛顿大学合作论文 375
    葛兰素史克合作论文 345
    阿斯利康合作论文 286
    密歇根大学合作论文 277
    安进合作论文 256
    基因泰克合作论文 245
    杜克大学合作论文 244

    机构统计